Press release
Lupus Nephritis Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Lupus Nephritis Therapeutics | DelveInsight
Key takeaways from the Lupus Nephritis Clinical Trial Landscape Report
• DelveInsight's Lupus Nephritis pipeline report depicts a robust space with 25+ active players working to develop 40+ pipeline therapies for Lupus Nephritis treatment.
• Key Lupus Nephritis companies such as Adicet Bio, Novartis, Kyverna Therapeutics, Century Therapeutics, Simcere Pharmaceutical Co., Ltd., and others
• Promising Lupus Nephritis pipeline therapies in various stages of development include Prulacabtagene leucel, Ianalumab, KYV-101, CNTY-101, SIM0278, and others.
Request a sample and discover the recent advances in Lupus Nephritis treatment drugs at: https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
What is Lupus Nephritis?
Lupus Nephritis is one of the most severe organ manifestations of systemic lupus erythematosus (SLE), an autoimmune disorder that causes inflammation and damage to the kidneys. Lupus nephritis occurs when the immune system attacks kidney tissues, leading to inflammation of the glomeruli and impaired kidney function. Symptoms include swelling, blood in urine, proteinuria, high blood pressure, and kidney dysfunction. If untreated, the disease can progress to chronic kidney disease or end-stage renal disease (ESRD). Diagnosis is based on blood tests, urine analysis, kidney biopsy, and imaging studies. Treatment includes corticosteroids, immunosuppressive therapies, monoclonal antibodies, and supportive renal care.
Emerging Lupus Nephritis Drug Profiles
Prulacabtagene leucel: Adicet Bio
Prulacabtagene leucel (ADI-001) is an allogeneic gamma-delta CAR T-cell therapy engineered to target CD20-expressing B cells involved in lupus nephritis. It is designed as an off-the-shelf cellular therapy intended to restore immune balance and reduce renal inflammation. The therapy is currently in Phase I clinical development for the treatment of Lupus Nephritis.
Ianalumab: Novartis
Ianalumab is a monoclonal antibody being developed for the treatment of Lupus Nephritis. The therapy is currently in Phase III clinical development and is being evaluated for its role in targeting autoimmune pathways associated with lupus nephritis progression.
Learn more about the novel and emerging Lupus Nephritis pipeline therapies at: https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Recent Developments in the Lupus Nephritis Clinical Trial Landscape
• In February 2026, Fate Therapeutics provided an update that the company is advancing towards the commencement of first planned Phase II clinical trial in Lupus Nephritis.
• In October 2025, Adicet Bio announced initial safety and efficacy data from the first seven patients dosed with ADI-001 in the ongoing Phase I study evaluating ADI-001 as a potential treatment for autoimmune diseases including Lupus Nephritis.
• In November 2025, Adicet Bio announced alignment with the US Food and Drug Administration (FDA) allowing Lupus Nephritis and SLE patients to be dosed with prula-cel in the outpatient setting in ongoing and future clinical trials.
• In June 2024, Adicet Bio announced that the US Food and Drug Administration (FDA) had granted Fast Track Designation to ADI-001 for the treatment of relapsed/refractory class III or class IV Lupus Nephritis.
• In March 2024, Lupus Therapeutics announced a collaboration with Artiva Biotherapeutics, Inc. on a Phase I trial evaluating AlloNK® in combination with anti-CD20 antibodies for patients with active Lupus Nephritis.
Scope of the Lupus Nephritis Pipeline Report
• Coverage: Global
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Preclinical, Phase I, Phase I/II, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Oral, Intravenous, Parenteral, Subcutaneous, Cell Injection
• Therapeutics Assessment By Molecule Type: Monoclonal antibody, CAR-T cell therapy, CAR-NK cell therapy, Recombinant fusion proteins, Gene therapy, Small molecule
• Key Lupus Nephritis Companies: Adicet Bio, Novartis, Kyverna Therapeutics, Century Therapeutics, Simcere Pharmaceutical Co., Ltd., and others
• Key Lupus Nephritis Pipeline Therapies: Prulacabtagene leucel, Ianalumab, KYV-101, CNTY-101, SIM0278, and others
Dive deep into rich insights for new drugs for Lupus Nephritis treatment, visit at: https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
Table of Contents
1. Lupus Nephritis Pipeline Report Executive Summary
2. Lupus Nephritis Pipeline: Overview
3. Analytical Perspective In-depth Commercial Assessment
4. Lupus Nephritis Pipeline Therapeutics
5. Lupus Nephritis Pipeline: Late Stage Products (Phase III)
6. Lupus Nephritis Pipeline: Mid Stage Products (Phase II)
7. Lupus Nephritis Pipeline: Early Stage Products (Phase I/II)
8. Lupus Nephritis Pipeline Therapeutics Assessment
9. Inactive Products in the Lupus Nephritis Pipeline
10. Company-University Collaborations (Licensing/Partnering) Analysis
11. Key Companies
12. Key Products in the Lupus Nephritis Pipeline
13. Unmet Needs
14. Market Drivers and Barriers
15. Future Perspectives and Conclusion
16. Analyst Views
17. Appendix
For further information on the Lupus Nephritis pipeline therapeutics, reach out at: https://www.delveinsight.com/sample-request/lupus-nephritis-pipeline-insight?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Lupus Nephritis Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping the Future of Lupus Nephritis Therapeutics | DelveInsight here
News-ID: 4512283 • Views: …
More Releases from DelveIinsight Business Research
Non-muscle Invasive Bladder Cancer (NMIBC) Market is Projected to Grow Significa …
The market dynamics for Non-muscle Invasive Bladder Cancer (NMIBC) are witnessing steady growth driven by the rising incidence and diagnosis rates of bladder cancer, increasing demand for effective bladder-preserving therapies, and growing adoption of advanced intravesical immunotherapies and gene therapies. Additionally, the launch of emerging therapies such as TAR-200 (Johnson & Johnson), UGN-102 (UroGen Pharma), Nadofaragene Firadenovec (Ferring Pharmaceuticals), and others will further fuel the market.
DelveInsight, a leading market research…
Nephrotic Syndrome Market is Expected to Witness Significant Growth by 2036 Due …
The market dynamics for Nephrotic Syndrome are witnessing steady growth driven by the increasing prevalence of kidney disorders, rising awareness and diagnosis of rare renal diseases, and advancements in biologic and immunosuppressive therapies. Additionally, the launch of emerging therapies and increasing focus on precision medicine approaches are expected to further fuel the Nephrotic Syndrome market during the forecast period.
DelveInsight, a leading market research firm, announces the release of its latest…
MASH Market is Projected to Boom by 2036 Owing to the Launch of Novel Therapies …
The market dynamics for MASH is witnessing steady growth driven by the rising Disease Prevalence and Diagnosis Rates, Increasing Demand for Effective Pharmacological Therapies, and Growing Preference for Personalized and Non-pharmacological Treatment Approaches. Additionally, the launch of emerging therapies such as Efruxifermin (Akero Therapeutics), VK2809 (Viking Therapeutics), Efimosfermin alfa (Boston Pharmaceuticals/GSK), and others will further fuel the market.
DelveInsight, a leading market research firm, announces the release of its latest report,…
Myasthenia Gravis Clinical Trial Pipeline Analysis: 25+ Key Companies Shaping th …
DelveInsight's Myasthenia Gravis Pipeline Insight 2026 report provides comprehensive global coverage of available, marketed, and pipeline Myasthenia Gravis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Myasthenia Gravis pipeline domain.
Key takeaways from the Myasthenia Gravis Clinical Trial Landscape Report
• DelveInsight's Myasthenia Gravis pipeline report depicts a robust space with 25+ active players working to develop 35+…
More Releases for Lupus
Cutaneous Lupus Erythematosus (CLE) Market
Introduction
Cutaneous Lupus Erythematosus (CLE) is a chronic autoimmune skin disorder, often associated with systemic lupus erythematosus (SLE), that presents as inflammation, rashes, and photosensitivity. While CLE is rarely fatal, it significantly affects patients' physical and emotional well-being, often leading to scarring, disfigurement, and social stigma.
Over the past decade, the market for CLE therapies has gained global importance as research into autoimmunity has accelerated and biologic therapies have transformed dermatology. Rising…
Prominent Cutaneous Lupus Erythematosus Market Trend for 2025: Advancements In C …
What combination of drivers is leading to accelerated growth in the cutaneous lupus erythematosus market?
The rising prevalence of skin infections is expected to drive the growth of the cutaneous lupus erythematosus (CLE) market. Skin infections are caused by microorganisms that invade the skin, triggering immune responses that can worsen symptoms in individuals with CLE. For example, the UK saw a 33.7% increase in MRSA cases caused by skin and soft…
Cutaneous Lupus Erythematosus (CLE) Market
Market Overview:
The Global Cutaneous Lupus Erythematosus (CLE) Market is forecasted to achieve a High CAGR during the period 2023-2030. CLE encompasses a spectrum of dermatological symptoms that may precede or accompany systemic lupus erythematosus (SLE), an autoimmune condition impacting multiple organs. Timely diagnosis and treatment of CLE can prevent the onset of severe systemic symptoms.
Market Dynamics:
Drivers:
Rise in Clinical Studies: Technological advancements leading to faster and accurate diagnosis have spurred additional…
Lupus Nephritis Treatment Market 2030
Global Lupus Nephritis Treatment market is expected to be worth roughly USD 8,048 million by 2030, growing at a CAGR of 7.3% during the forthcoming period of 2022-2030, according to Ameco Research
Lupus nephritis is one of the most rapidly spreading diseases over the globe. The increasing frequency of lupus nephritis and consumer awareness has fuelled the worldwide lupus nephritis treatment market. Another crucial factor driving the pace of growth of…
Lupus Erythematosus Market -API Insights, 2017
Summary
Orbis Research Present “Lupus Erythematosus-API Insights, 2017”
Description
The active pharmaceutical ingredients worldwide market is in continuous development from the recent years. There is expected to be a major impact on the global API industry, with the large number of blockbuster drugs going off patent in the coming years. It is going to affect the revenue of the API market as generic drugs occupy the market.
India and China produce a large percentage…
Global Systemic Lupus Erythematosus and Lupus Nephritis Market to Display 10.6% …
"The Report PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2025 provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
MarketResearchReports.biz has announced the addition of a new report, titled “PharmaPoint: Systemic Lupus Erythematosus And Lupus Nephritis - Global Drug Forecast And Market Analysis To 2025,” to its expanding repository of research reports. The market…
